Welcome to our dedicated page for Spectral AI news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. (Nasdaq: MDAIW for its redeemable warrants) is a Dallas-based predictive AI company focused on medical diagnostics in wound care, with initial applications in burn treatment. Company news updates center on the development, clinical use, and regulatory progress of its DeepView System, a non-invasive device and software platform that combines multispectral imaging with proprietary AI algorithms to assess burn wound healing potential.
News coverage for Spectral AI frequently includes announcements about the DeepView System’s role at major burn conferences, such as the British Burn Association, European Burns Association, and regional U.S. burn meetings. These reports describe presentations and posters on topics like AI-enhanced multispectral imaging, real-world burn healing studies, reader studies evaluating clinicians’ ability to detect non-healing wounds, and patient experience with AI-based imaging in burn consultations.
Investors and healthcare professionals can also find updates on Spectral AI’s financial results, including research and development revenue tied to its BARDA Project BioShield contract, cash position, and financing activities that support ongoing DeepView development. Regulatory milestones, such as the submission of a De Novo 510(k) marketing clearance application to the U.S. Food and Drug Administration for DeepView’s use in burn care settings, are another recurring theme in the company’s news releases.
By following Spectral AI news, readers can track how the company reports progress on its AI-driven DeepView technology, its participation in clinical and professional forums, and its efforts to position DeepView as a predictive diagnostic tool in burn and wound care.
Spectral AI (Nasdaq: MDAI) announced reaching 50% patient enrollment in its U.S. pivotal burn study, with 90 out of a target 240 patients enrolled. The study aims to validate the algorithm of the DeepView™ System, which utilizes AI for rapid and accurate assessment of burn wounds. Expected to complete enrollment by 2025, this trial represents the final step before seeking FDA approval. The DeepView™ System's efficacy will be compared against current clinician assessments. The system's image processing algorithm, trained on over 340 billion data points, is designed to enhance burn care by providing objective assessments to improve patient outcomes and reduce healthcare costs.
Spectral AI (Nasdaq: MDAI), an AI-driven medical diagnostics firm, announced its scheduled inclusion in the Russell Microcap® Index following the 2024 Russell US Indexes reconstitution, effective June 28, 2024. The company's proprietary DeepView™ System, which assesses wound healing potential, received UKCA Authorization and is expected to generate its first commercial revenue later in 2024. Spectral AI was also awarded a $150 million contract from the US Government for the DeepView™ System's advanced development. For Q1 2024, the company reported a 24.6% increase in R&D revenue, totaling $6.3 million, and a cash position of $10.2 million.
Spectral AI (Nasdaq: MDAI), an AI company specializing in medical diagnostics for wound care, announced its participation in Benzinga’s “AI Unleashed: Exploring the Possibilities” virtual event on May 30, 2024. CEO Peter M. Carlson will represent the company in a fireside chat starting at 11:25 am ET. The event will be live-streamed and accessible through the company's investor portal. This event serves as a platform for Spectral AI to showcase its advancements and future prospects in AI-driven medical diagnostics.
Spectral AI announced that its officers and directors purchased approximately 113,000 shares of its common stock in open market transactions on May 10 and May 15, 2024. The company is progressing toward commercializing its AI-driven DeepView™ System, which assesses wound healing potential, with initial applications in burns and diabetic foot ulcers. After receiving UKCA Authorization in February, Spectral AI plans to generate its first commercial product revenue in the second half of 2024. The company continues to advance clinical studies in the US and UK and aims to file additional regulatory submissions in 2024 and 2025. A $150 million multi-year contract from the US Government was awarded in September 2023 for the DeepView™ System's development, contributing to a total of $250 million in non-dilutive support. For Q1 2024, Research & Development revenue rose by 24.6% to $6.3 million, improving the company's cash position to $10.2 million.
Spectral AI (Nasdaq: MDAI) announced the results of its 2024 Annual Meeting of Stockholders held on May 14, 2024. Key outcomes include the election of six directors to serve until the next Annual Meeting, and the approval of four proposals. Newly elected directors are Richard Cotton, Peter M. Carlson, Dr. J. Michael DiMaio, Martin Mellish, Deepak Sadagopan, and Marion Snyder. Additionally, stockholders ratified the adoption of the 2023 Long Term Incentive Plan, the appointment of KPMG LLP as the company's independent auditor for the 2024 fiscal year, and the reservation and issuance of shares of common stock pursuant to the Standby Equity Purchase Agreement. The Board also expanded to seven members and appointed Erich Spangenberg as a new director, who had previously declined to stand for reelection but accepted the Board’s request to serve.
Spectral AI, Inc. (Nasdaq: MDAI) announced their Q1 2024 financial results, showcasing a $6.3 million Research & Development revenue, cash reserves of $10.2 million, and the deployment of DeepView AI®-Burn devices in the UK with expected commercial revenue in 2H 2024. The company plans further regulatory submissions in the US and UK for the DeepView™ System in 2024 and 2025.
Spectral AI, Inc. (Nasdaq: MDAI) will be participating in the Sidoti Micro-Cap Virtual Investor Conference on May 8-9, 2024. The company focuses on AI for medical diagnostics in wound care. Interested parties can access the live presentation and webcast on the company's website. Registration for the event is free.
Spectral AI, Inc. (Nasdaq: MDAI) received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center for their UKCA Mark Attainment. The award recognizes the company's leadership in the Texas Manufacturing space and their dedication to innovation in wound care through DeepView™ technology. TMAC, associated with MEP-NIST, supports Texas manufacturers with business consulting, technology implementation, workforce development, and strategic planning.
Summary not available.
Summary not available.